United Therapeutics Corp (NAS:UTHR)
$ 265.91 4.96 (1.9%) Market Cap: 11.80 Bil Enterprise Value: 9.48 Bil PE Ratio: 12.58 PB Ratio: 2.20 GF Score: 89/100

Q4 2018 United Therapeutics Corp Earnings Call Transcript

Feb 27, 2019 / 02:00PM GMT
Release Date Price: $125.54 (+2.94%)
Operator

Good morning, and welcome to United Therapeutics Corporation Fourth Quarter and Full Year 2018 Earnings Call. My name is Nicole, I will be your conference operator today. (Operator Instructions) I'd now like to turn the conference over to James Edgemond, Chief Financial Officer of United Therapeutics.

James C. Edgemond
United Therapeutics Corporation - CFO & Treasurer

Thank you. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter and Full Year 2018 Earnings Call. Accompanying me on today's call are Dr. Roth -- Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer. And in addition, we are pleased to welcome to this earnings call, Dr. Jim White, Professor of Medicine, Pharmacology and Physiology in the Division of Pulmonary and Critical Care Medicine at the University of Rochester Medical Center, and a steering committee member for the FREEDOM-EV study of Orenitram. Dr. White will be available during the question-and-answer portion of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot